

Drug Development for Cognitive Impairment in Schizophrenia: History: What we did Right, Unanticipated Problems and Solutions

Stephen R. Marder, MD

**Semel Institute for Neuroscience and
Human Behavior at UCLA**

**VA Mental Illness Research, Education,
and Clinical Center (MIRECC)**

NIMH/MATRICES Approach to a Clinical Target


Use a consensus building process to

- Define the basic elements (separable domains) of the target
- Develop methods for measuring each element as a potential endpoint in clinical trials
- Develop a clinical trials methodology
- Develop animal models
- Prioritize molecular targets

What we did right

- Broad representation of academia and industry including neuroscientists, experts in cognition and its measurement, and others
- FDA participation from the start
- A predetermined path to consensus
- Transparency

Steps to MATRICS-NIMH Consensus Battery



*NCC: MATRICS Neurocognition Committee

**PASS: MATRICS Psychometric and Standardization Study

Surprises

- Reactions of test developers
- Need to form a non-profit
- Need for a co-primary measure

What we could have done better

- More international involvement in all MATRICS processes
- Developing a process for evaluating and updating MATRICS products and recommendations.